Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients - Seattle, Washington, 2009 - PubMed (original) (raw)
Case Reports
. 2009 Aug 21;58(32):893-6.
- PMID: 19696719
Free article
Case Reports
Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients - Seattle, Washington, 2009
Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2009.
Free article
Abstract
Novel influenza A (H1N1) virus infection continues to cause illness and death among persons worldwide. Immunosuppressed patients with influenza virus infection can shed virus for prolonged periods, increasing the chances for development of drug resistance. On August 6, 2009, CDC detected evidence of resistance to the antiviral medication oseltamivir in two severely immunosuppressed patients with novel influenza A (H1N1) virus infection in Seattle, Washington. The two patients were treated in two different hospitals, and their cases were not epidemiologically linked. Both were being treated with oseltamivir for novel influenza A (H1N1) virus infection and had prolonged viral shedding. In both patients, the virus was documented as initially susceptible to oseltamivir, and resistance developed subsequently during treatment with the drug. Testing of viral RNA from both patients by pyrosequencing detected a mutation that results in a histidine-to-tyrosine substitution at position 275 (H275Y) in the neuraminidase, known to be associated with oseltamivir resistance. The results were confirmed by pyrosequencing, sequencing of the neuraminidase gene, and neuraminidase inhibition testing of virus isolates on August 11. One patient's symptoms resolved after treatment with oseltamivir, and the other patient was receiving treatment with zanamivir and ribavirin as of August 13. An investigation of health-care personnel (HCP) contacts and other close contacts revealed no evidence of virus transmission. This report summarizes the case histories and resulting investigations and highlights the importance of 1) close monitoring for antiviral drug resistance among immunosuppressed patients receiving treatment for novel influenza A (H1N1) virus infection and 2) the implications for infection control.
Similar articles
- Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis--North Carolina, 2009.
Centers for Disease Control and Prevention (CDC). Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2009 Sep 11;58(35):969-72. MMWR Morb Mortal Wkly Rep. 2009. PMID: 19745803 - Development of oseltamivir and zanamivir resistance in influenza A(H1N1)pdm09 virus, Denmark, 2014.
Trebbien R, Pedersen SS, Vorborg K, Franck KT, Fischer TK. Trebbien R, et al. Euro Surveill. 2017 Jan 19;22(3):30445. doi: 10.2807/1560-7917.ES.2017.22.3.30445. Euro Surveill. 2017. PMID: 28128091 Free PMC article. - Detection of the rapid emergence of the H275Y mutation associated with oseltamivir resistance in severe pandemic influenza virus A/H1N1 09 infections.
Wang B, Dwyer DE, Blyth CC, Soedjono M, Shi H, Kesson A, Ratnamohan M, McPhie K, Cunningham AL, Saksena NK. Wang B, et al. Antiviral Res. 2010 Jul;87(1):16-21. doi: 10.1016/j.antiviral.2010.04.002. Epub 2010 Apr 10. Antiviral Res. 2010. PMID: 20385168 - Emerging oseltamivir resistance in seasonal and pandemic influenza A/H1N1.
Renaud C, Kuypers J, Englund JA. Renaud C, et al. J Clin Virol. 2011 Oct;52(2):70-8. doi: 10.1016/j.jcv.2011.05.019. Epub 2011 Jun 17. J Clin Virol. 2011. PMID: 21684202 Review. - Emergence of oseltamivir resistance: control and management of influenza before, during and after the pandemic.
Dixit R, Khandaker G, Ilgoutz S, Rashid H, Booy R. Dixit R, et al. Infect Disord Drug Targets. 2013 Feb;13(1):34-45. doi: 10.2174/18715265112129990006. Infect Disord Drug Targets. 2013. PMID: 23675925 Review.
Cited by
- Comparative Analysis of Clinical Outcomes for COVID-19 and Influenza among Cardiac Transplant Recipients in the United States.
Chavarin DJ, Bobba A, Davis MG, Roth MA, Kasdorf M, Nasrullah A, Chourasia P, Gangu K, Avula SR, Sheikh AB. Chavarin DJ, et al. Viruses. 2023 Aug 5;15(8):1700. doi: 10.3390/v15081700. Viruses. 2023. PMID: 37632042 Free PMC article. - Ebselen and Diphenyl Diselenide Inhibit SARS-CoV-2 Replication at Non-Toxic Concentrations to Human Cell Lines.
Wildner G, Tucci AR, Prestes AS, Muller T, Rosa ADS, Borba NRR, Ferreira VN, Rocha JBT, Miranda MD, Barbosa NV. Wildner G, et al. Vaccines (Basel). 2023 Jul 10;11(7):1222. doi: 10.3390/vaccines11071222. Vaccines (Basel). 2023. PMID: 37515038 Free PMC article. - A systemic review on medicinal plants and their bioactive constituents against avian influenza and further confirmation through in-silico analysis.
Dutta AK, Gazi MS, Uddin SJ. Dutta AK, et al. Heliyon. 2023 Mar 10;9(3):e14386. doi: 10.1016/j.heliyon.2023.e14386. eCollection 2023 Mar. Heliyon. 2023. PMID: 36925514 Free PMC article. Review. - A large effective population size for established within-host influenza virus infection.
Lumby CK, Zhao L, Breuer J, Illingworth CJ. Lumby CK, et al. Elife. 2020 Aug 10;9:e56915. doi: 10.7554/eLife.56915. Elife. 2020. PMID: 32773034 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous